Biomarkers to Safely Discharge Head Trauma Patients in the Covid-19 Pandemic Era

Alexiou, George Α.; Lianos, Georgios D; Alexiou, E.; Voulgaris, Spyridon

doi:10.2217/bmm-2021-0008

Cited by 4 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The full texts of the remaining 47 studies were reviewed, and 26 studies were subsequently excluded based on the eligibility criteria. Among the excluded studies, 15 did not report outcomes of interest (NfL and GFAP) in both COVID-19 and healthy controls [30,31,[38][39][40][41][42][43][44][45][46][47][48][49][50], six did not include healthy controls [31,36,38,44,48,51], three were reviews [8,52,53], and two were editorial reports [54,55]; note that a few reports belonged to more than one category. Finally, 21 studies that reported mean (±SD) or median (±IQR) values for NfL and GFAP were included in the meta-analysis (Figure 1).…”

Section: Study Search Selection and Characteristicsmentioning

confidence: 99%

Blood Biomarkers as Prognostic Indicators for Neurological Injury in COVID-19 Patients: A Systematic Review and Meta-Analysis

Huang,

Haile,

Gedefaw

et al. 2023

IJMS

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has been linked to various neurological complications. This meta-analysis assessed the relationship between glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) levels in the blood and neurological injury in COVID-19 patients. A comprehensive search of various databases was conducted until 18 August 2023, to find studies reporting GFAP and NfL blood levels in COVID-19 patients with neurological complications. GFAP and NfL levels were estimated between COVID-19 patients and healthy controls, and meta-analyses were performed using RevMan 5.4 software for analysis. In the 21 collected studies, it was found that COVID-19 patients had significantly higher levels of pooled GFAP (SMD = 0.52; 95% CI: 0.31, 0.73; p ≤ 0.001) and NfL (SMD = 0.60; 95% CI: 0.37, 0.82; p ≤ 0.001) when compared to the healthy controls. The pooled GFAP (SMD = 0.86; 95% CI: 0.26, 1.45; p ≤ 0.01) and NfL (SMD = 0.87; 95% CI: 0.48, 1.26; p ≤ 0.001) were significantly higher in non-survivors. These findings indicate a significant association between COVID-19 severity and elevated levels of GFAP and NfL, suggesting that GFAP and NfL could serve as potential diagnostic and prognostic markers for the early detection and monitoring of COVID-19-related neurological injuries.

show abstract

Section: Study Search Selection and Characteristicsmentioning

confidence: 99%

Blood Biomarkers as Prognostic Indicators for Neurological Injury in COVID-19 Patients: A Systematic Review and Meta-Analysis

Huang,

Haile,

Gedefaw

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…The only effective measure that was suggested against pandemic was lockdowns that lasted for different time intervals depending on the virus' metrics in each region 3 . However, public and political attention during lockdowns was mainly focused on the economic impact of restrictions, whereas their impact on patients' health issues, especially cancer, has generally been underestimated 4 …”

Section: Introductionmentioning

confidence: 99%

“…3 However, public and political attention during lockdowns was mainly focused on the economic impact of restrictions, whereas their impact on patients' health issues, especially cancer, has generally been underestimated. 4…”

mentioning

confidence: 99%

Surgical oncology during the post‐COVID‐19 era: What is next?

Lianos

Frountzas

Schizas

et al. 2022

Journal of Surgical Oncology

View full text Add to dashboard Cite

During first outburst of COVID-19, several strategies had been applied for surgical oncology patients to minimize COVID-19 transmission. COVID-19 infection seemed to compromise survival and major complication rates of surgical oncology patients.However, survival, tumor progression and recurrence rates of surgical oncology patients were associated to the consequences of COVID-19 pandemic on their management. In addition, the severity of COVID-19 infections has been downgraded. Therefore, management of surgical oncology patients should be reconsidered.

show abstract